Related Experiment Videos
Risperidone in combination with mood stabilizers: a 10-week continuation phase study in bipolar I disorder
Charles L Bowden1, Joyce E Myers, Fred Grossman
1University of Texas Health Science Center, San Antonio, TX 78229, USA. bowdenc@uthscsa.edu
The Journal of Clinical Psychiatry
|May 28, 2004
Summary
Combination therapy with risperidone and a mood stabilizer effectively treated acute manic episodes in bipolar disorder patients. This combination therapy demonstrated efficacy and good tolerability in continuation treatment.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Assessed combination therapy (risperidone and mood stabilizer) for bipolar disorder patients hospitalized for manic episodes.
- Utilized DSM-IV criteria for patient diagnosis.
Purpose of the Study:
- To evaluate the efficacy and tolerability of combination therapy for acute manic episodes.
- To assess continuation treatment with risperidone and mood stabilizers.
Main Methods:
- 13-week study involving flexible doses of mood stabilizers (lithium or divalproex) with placebo, risperidone, or haloperidol.
- Followed by a 10-week open-label phase with risperidone and mood stabilizer combination.
- Utilized Young Mania Rating Scale (YMRS) for efficacy assessment.
Main Results:
- Significant reductions in YMRS scores observed with risperidone plus mood stabilizer compared to placebo plus mood stabilizer.
- High symptom remission rates (79%) achieved by the end of the 10-week study.
- Improvements noted across Brief Psychiatric Rating Scale, Hamilton Rating Scale for Depression, and Clinical Global Impressions scales.
Conclusions:
- Combination of risperidone and a mood stabilizer is efficacious for acute manic episodes.
- This combination therapy is well-tolerated for continuation treatment.
- Treatment demonstrated significant efficacy in managing manic episodes and related symptoms.